Sellas Life Sciences Group Inc (SLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 71,893 | 44,420 | 25,397 | 28,497 | 13,986 |
| TOTAL | $75,211 | $49,051 | $29,447 | $31,973 | $16,327 |
| Non-Current Assets | |||||
| Intangibles | 1,914 | 1,914 | 1,914 | 1,914 | 1,914 |
| Other Non-Current Assets | 1,220 | 590 | 944 | 1,069 | 1,191 |
| TOTAL | $3,134 | $2,504 | $2,858 | $2,983 | $3,105 |
| Total Assets | $78,345 | $51,555 | $32,305 | $34,956 | $19,432 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,948 | 2,305 | 3,336 | 3,756 | 3,500 |
| Accrued Expenses | 3,525 | 3,021 | 2,083 | 2,571 | 5,466 |
| TOTAL | $7,017 | $5,925 | $5,999 | $6,888 | $9,510 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 457 | 0 | 157 | 309 | 457 |
| TOTAL | $457 | $N/A | $157 | $309 | $457 |
| Total Liabilities | $7,474 | $5,925 | $6,156 | $7,197 | $9,967 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 179,583 | 142,442 | 105,298 | 99,777 | 90,847 |
| Common Shares | 15 | 12 | 10 | 9 | 7 |
| Retained earnings | -274,988 | -267,330 | -260,539 | -253,938 | -248,125 |
| TOTAL | $70,871 | $45,630 | $26,149 | $27,759 | $9,465 |
| Total Liabilities And Equity | $78,345 | $51,555 | $32,305 | $34,956 | $19,432 |